Skip to main content
. 2022 Jun 10:101–135. doi: 10.1016/B978-0-323-85156-5.00021-3

Table 6.7.

Clinical trials performed with the supporting agents.

Trial registration code Trial type Total number of patients enrolled/participants Objective/Outcome References
2020-000890-25 Randomized clinical trial 36 Azithromycin added to hydroxychloroquine exhibited significantly more efficiency in eliminating virus. [74,119]
NCT04264533 Randomized trial 140 Number of ventilation-free days determined on the 28th day of enrollment.
28 days mortality monitoring of patient survival.
Duration of stay in ICU.		 [120]
NCT04341675 Randomized trial 30 Number of patients who are alive and not dependent on advanced respiratory support on 28th day.
Number of patients requiring intensification in care.
Change in specific biomarkers such as LDH, ferritin, D-dimer, lymphocyte count over time.
Number of surviving patients to discharge from hospital.		 [121]
NCT03901001 Randomized trail 160 In time frame of 28 days:

  • (a) Respiratory status to normalcy

  • (b) Copies of viral ribonucleic acid (RNA) per milliliter.

In time frame of 10 days:
Levels of interleukin, chemokine ligand 9, soluble tumor necrosis factor receptor-1, phospho-p38, and phospho-ERK.		 [122]
NCT04305457 Randomized, interventional (clinical trial) 240 Decrease in requirement of intubation and mechanical ventilation in patients having mild to moderate COVID-19 symptoms. [123]
NCT04306393 Randomized, interventional (clinical trial) 200 Change of arterial oxygenation at 48 h from enrollment.
Time to reach normoxemia during the first 28 days after enrollment.
Proportion of SARS-nCoV-2–free patients during the first 28 days after enrollment.		 [124]
ChiCTR2000029765 Interventional study 188 Evaluation of safety and effectiveness of tocilizumab in treatment of regular patients with NCP (including severe risk factors) and critical NCP patients.
Outcome: Ventilator utilization.		 [125]
NCT04315298 Randomized interventional clinical trial 2500 Evaluation of change in C-reactive protein (CRP) (%) levels in patients with serum interleukin-6 level greater than the upper limit.
Proportion of patients with at least 1-point improvement in clinical status using the 7-point ordinal scale in patients with critical COVID-19 treated with mechanical ventilation at baseline.		 [126]